Instituto San Marcos Investigación - San Juan

Somos un Centro de Investigación con un equipo interdisciplinario de profesionales con amplia formación académica, experiencia y, principalmente, compromiso con el ejercicio de la profesión y la atención de nuestros pacientes.
logoInstituto San Marcos Investigación - San Juan
Sarmiento 92 norte, San Juan
Select an option

Specializations

Cáncer de estómago
Oncología
Infectología
Hematología

Our team

Medical staff
Alvaro Yanzi
Gabriel Agüero
Alejandro Roses Videla
Virginia Canónico
Rosa Contreras

Open studies

Breast Cancer
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer - EMBER-4 - Eli Lilly and CompanySee more
Esophageal cancer
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014) - LEAP-014 - Merck Sharp & Dohme Corp.See more
Kidney cancer
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) - MK-3475A-F11 - Merck Sharp & Dohme LLCSee more
Lung cancer
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) - MK-3475A-F11 - Merck Sharp & Dohme LLCSee more
Skin cancer
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) - MK-3475A-F11 - Merck Sharp & Dohme LLCSee more
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy